At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 30 target
Drug / intervention
Yutiq 0.18 MG Drug Implant +1 moredrug
Likely dose
Yutiq 0.18 MG Drug Implantfrom record
Key inclusion· 7
- ✓Male or non-pregnant female at least 18 years of age
- ✓Chronic noninfectious posterior segment inflammation with or without anterior uveitis
- ✓Prior clinical response to ≥1 corticosteroid treatment with recurrence indicating chronicity
- ✓Active posterior segment inflammation
Key exclusion· 13
- ✕Anterior uveitis only without posterior segment involvement
- ✕Vitreous hemorrhage present
- ✕Infectious etiology uveitis
- ✕Intraocular inflammation from condition other than noninfectious uveitis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
In Brief
A Phase 3 clinical trial evaluating Yutiq 0.18 MG Drug Implant and Sham Injection for Uveitis and 3 related conditions. Currently recruiting, targeting 30 participants across 1 site.
Detailed Summary
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
CountriesUnited States
CollaboratorsEye Point Pharmaceuticals, ANI Pharmaceuticals
Timeline
Phase 3Recruiting
20232024202520262027
First PostedAug 2022
Enrollment StartOct 2022
Primary CompletionJul 2026
TodayJul 2026
Study CompletionDec 2026
First PostedAug 3, 2022
Enrollment StartOct 5, 2022
Primary CompletionJul 1, 2026
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 3.9 years ago
Interventions
Yutiq 0.18 MG Drug Implantdrug
YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
Sham Injectionother
Sham injection